Effect of rheumatoid arthritis or systemic lupus erythematosus on the risk of First-Time acute myocardial infarction

doi:10.1016/j.amjcard.2003.09.037

The American Journal of Cardiology

Volume 93, Issue 2, 15 January 2004, Pages 198-200

https://doi.org/10.1016/j.amjcard.2003.09.037 Get rights and content

Abstract

We explored the association between diagnosed rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE) and the risk of developing a first-time acute myocardial infarction (AMI) by conducting a population-based, case-control analysis using data from the United Kingdom-based General Practice Research Database (GPRD). Among 8,688 patients with AMI and 33,329 matched controls, the adjusted odds ratio (ORs) of AMI for subjects with RA was 1.47 (95% confidence interval [CI] 1.23 to 1.76), and in subjects with both RA and diagnosed hyperlipidemia, the OR was 7.12 (95% CI 4.16 to 12.18). The risk associated with SLE was 2.67 (95% CI 1.34 to 5.34). These results underline that RA and SLE increase the risk of AMI.

References (15)

H. Jick
A database worth saving
Lancet
(1997)
C.R. Meier et al.
Acute respiratory tract infections and risk of first-time acute myocardial infarction
Lancet
(1998)
R. Ross
Atherosclerosis—an inflammatory disease
N Engl J Med
(1999)
D.H. Solomon et al.
Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis
Circulation
(2003)
S. Wallberg-Jonsson et al.
Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden
J Rheumatol
(1997)
I.D. del Rincon et al.
High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors
Arthritis Rheum
(2001)
S. Manzi et al.
Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosuscomparison with the Framingham Study
Am J Epidemiol
(1997)

There are more references available in the full text version of this article.

Cited by (198)

CardioRheumatology
2021, Sex Differences in Cardiac Diseases: Pathophysiology, Presentation, Diagnosis and Management
A 41-year-old female patient with a history of systemic lupus erythematosus presents to the emergency room with symptoms of chest pain. The pain is described as sharp and midsternal, with radiation to the left shoulder. The pain started while at rest and has been constant, although worsens with activity and deep breaths. There is associated shortness of breath but no diaphoresis, nausea, or lightheadedness. No additional symptoms of syncope or edema. The week prior she had experienced symptoms of a cough, malaise, and subjective fevers/chills. The patient was diagnosed with lupus in her late 20s when she presented with profound fatigue and joint pain as well as a malar rash. She is maintained on mycophenolate mofetil and prednisone 5 mg daily. Currently, she is experiencing some increase in the pain in her hands and feet, along with the aforementioned recent chest pain.
Upon presentation to the emergency room, her blood pressure was 112/78, heart rate 82. Her physical exam was remarkable for a malar rash, mild lower extremity edema, and a soft pericardial friction rub. An electrocardiogram was done in the emergency room (Figure 1) and did not show evidence of an acute myocardial infarction. Pertinent labs included a normal white blood cell count, mild anemia, a sedimentation rate of 95 mm/1 h (normal ≤ 29 mm/1 h), and C-reactive protein of 177 mg/L (normal ≤ 9 mg/L). Cardiac biomarkers revealed a troponin T of 0.17 ng/mL at 0 h, 0.19 ng/mL at 3 h, and 0.21 ng/mL at 6 h (normal ≤ 0.01 ng/mL). How would you manage this patient?
Women have an increased risk of certain chronic autoimmune inflammatory disorders (CIDs). All aspects of the heart’s structure and function may be affected by the autoimmune disease. Many of the cardiovascular (CV) complications may be clinically silent and subclinical. However, there is still a clear burden of increased CV morbidity and mortality in these patients. Despite the growing recognition of the increased CV risk in the inflammatory autoimmune patient population, at present there are no specific guidelines that address the risk. A heightened awareness of the CV risk is important as one evaluates and treats the CID patient. Although the CID patient may not report CV symptomatology, their ongoing inflammatory condition may be resulting in damage to the entire cardiac system.
Autoimmune Rheumatic Diseases and Premature Atherosclerotic Cardiovascular Disease: An Analysis From the VITAL Registry
2020, American Journal of Medicine
Although the association between autoimmune rheumatic diseases and atherosclerotic cardiovascular disease is well-known, there is a lack of data regarding the role of such disorders in patients with premature and extremely premature atherosclerotic cardiovascular disease.
The Veterans With Premature Atherosclerosis (VITAL) registry, including patients with premature (males <55 years, females <65 years) and extremely premature atherosclerotic cardiovascular disease (<40 years), was created from the 2014-2015 nationwide Veterans Affairs (VA) health care system database. We assessed age at the time of first cardiovascular event to compare patients with premature (n = 135,703) and those with extremely premature atherosclerotic cardiovascular disease (n = 7716) with age-matched patients without atherosclerotic cardiovascular disease (n_young = 1,153,535, n_{extremely young} = 441,836). We assessed whether systemic lupus erythematosus, rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis were independently associated with premature and extremely premature atherosclerotic cardiovascular disease.
Patients with premature and extremely premature atherosclerotic cardiovascular disease had a higher prevalence of all rheumatic diseases as compared with age-matched patients without atherosclerotic cardiovascular disease. In fully adjusted models, systemic lupus erythematosus (odds ratio [OR]: 1.69, 95% confidence interval [CI]: 1.56-1.83) and rheumatoid arthritis (OR: 1.72, 95% CI: 1.63-1.81) were associated with increased odds of premature atherosclerotic cardiovascular disease. Patients with systemic lupus erythematosus (OR: 3.06, 95% CI: 2.38-3.93) and rheumatoid arthritis (OR: 2.39, 95% CI: 1.85-3.08) also had a higher likelihood of extremely premature atherosclerotic cardiovascular disease.
Patients with systemic lupus erythematosus and rheumatoid arthritis carry higher odds of both premature and extremely premature atherosclerotic cardiovascular disease. Future studies are needed to understand the rheumatic disease-specific factors behind the development and progression of clinical atherosclerotic cardiovascular disease in these young patients.
Association of acute myocardial infarction with seropositive rheumatoid arthritis in Korea: A nationwide longitudinal cohort study
2020, Journal of Clinical Neuroscience
The aim of this nationwide age- and sex matched longitudinal follow up study is to determine the risk of acute myocardial infarction (AMI) associated with the seropositive rheumatoid arthritis (RA) population in Korea.
Patient data were collected from the National Health Insurance Service Health Screening cohort. RA was identified using the International Classification of Diseases code M05 (seropositive RA), with a prescription of any disease-modifying anti-rheumatic drug (DMARD). A total of 2,765 patients were enrolled in the seropositive RA group from January 1, 2004 to December 31, 2015 from the NHIS. The control group consisted of 13,825 subjects. The 12-years AMI incidence rate for each group was calculated using the Kaplan-Meier method. A Cox proportional-hazards regression analysis was used to estimate the hazard ratio of AMI.
During the follow-up period, 39 patients (1.41%) in the seropositive RA group and 111 (0.80%) in the control group experienced AMI (P = 0.003). The hazard ratio of AMI in the seropositive RA group was 3.879 (95% confidence interval (CI): 2.64–5.68) after adjusting for age and sex. The adjusted hazard ratio of AMI in the seropositive RA group was 4.212 (95% CI: 2.86–6.19) after adjusting for demographics and comorbid medical disorders. According to subgroup analysis, in male and female and the non-diabetes and non-hypertension and hypertension and dyslipidemia and non-dyslipidemia subgroups, AMI incidence rates were significantly higher in the seropositive RA group than in the control group.
Our nationwide longitudinal study suggests an increased risk of AMI in seropositive RA patients.
Prediction of Major Adverse Cardiovascular Events by Triglyceride Glucose Index in Predominantly Male Patients with Rheumatoid Arthritis
2024, Reviews in Cardiovascular Medicine
Comorbidities among Egyptian systemic lupus erythematosus: The COMOSLE-EGYPT study
2023, Chronic Illness
Inflammatory bowel disease patients have an increased risk of acute coronary syndrome: a systematic review and meta-analysis
2023, Open Heart

View all citing articles on Scopus

^☆: The Boston Collaborative Drug Surveillance Program was partly supported by grants from Hoffmann-La Roche, Basel, Switzerland. This study was not directly funded. Dr. Meier was supported by a grant from the Swiss National Science Foundation (grant No 32-67808.02), Basel, Switzerland. Dr. Matter was supported by the EU grant G5RD-CT-2001-00532, Brussels, Belgium; and by grant 02.0057 from the Bundesamt für Bildung und Wissenschaft, Bern, Switzerland.

View full text

Effect of rheumatoid arthritis or systemic lupus erythematosus on the risk of First-Time acute myocardial infarction☆

Abstract

Lancet

Lancet

Atherosclerosis—an inflammatory disease

N Engl J Med

Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis

Circulation

Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden

J Rheumatol

High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors

Arthritis Rheum

Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosuscomparison with the Framingham Study

Am J Epidemiol